San Francisco, 3 April 2019: The Report Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report
By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy,
Drug), By Disease Type, And Segment Forecasts, 2018 - 2025
The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025,
according to a new report by Grand View Research, Inc. It is estimated to
register a CAGR of 12.9% during the forecast period. Due to the rare nature and
complexity of these diseases, scientific knowledge pertaining to them is
scarce. However, there are various initiatives undertaken to increase awareness
regarding rare diseases and to support SMA communities. This is anticipated to
boost the market development over the coming years.
Various SMA communities
and companies have collaborated for developing disease treatment therapy. For
example, RG7916, which is an investigational therapy being developed by Roche
in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy
investments in R&D by major companies are also projected to contribute
toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are
some of the organizations actively supporting R&D pertaining to SMA.
CureSMA provided funding
to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing
Spinraza, which received U.S. FDA approval in 2016. This organization has
invested nearly USD 70 million in the research pertaining to SMA, which also
included a planned investment of USD 5 million in the coming years.
Access
Research Report of SMA Treatment Market @ https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market
Further key findings from the study suggest:
· The global spinal muscular atrophy
treatment market is projected to expand at a CAGR of 12.9% over the forecast
period
· Based on disease type, type 1 accounted for
the largest revenue share owing to rising incidence of type 1 SMA
· By treatment, the drug segment accounted
for the largest revenue share in 2017
· North America will retain its lead as the
largest regional market; however Asia Pacific is anticipated to register the
fastest CAGR over the forecast period
· Themarket is presently led by Biogen Inc.
Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing
to which market is not competitive. However, this trend is expected to change
after the commercialization of other treatment therapies post 2020
Browse more reports of this category by Grand View
Research at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global spinal muscular atrophy treatment market on the basis of
disease type, treatment, route of administration, and region:
SMA Treatment Disease Type Outlook (Revenue,
USD Million, 2015 - 2025)
·
Type 1
·
Type 2
·
Type 3
·
Type 4
SMA Treatment Outlook (Revenue, USD Million, 2015 -
2025)
·
Gene Therapy
·
Drug
SMA Treatment Route of Administration Outlook (Revenue,
USD Million, 2015 - 2025)
·
Oral
·
Intrathecal
SMA Treatment Regional Outlook (Revenue,
USD Million, 2015 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Access Press Release of
SMA Treatment Market@ https://www.grandviewresearch.com/press-release/global-spinal-muscular-atrophy-sma-treatment-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment